Chuikyo OKs Listing of Litfulo and More; 10 Billion-Plus Yen Peak Sales for Pfizer, Sobi Meds

The Central Social Insurance Medical Council (Chuikyo) on August 23 approved a roster of new medicines for reimbursement listing, including Pfizer’s refractory alopecia areata (AA) therapy Litfulo (ritlecitinib). The drugs will be added to the NHI price list on August...read more